Coherus Oncology (CHRS) Enterprise Value Growth (3y) (2016 - 2026)

Coherus Oncology (CHRS) Enterprise Value Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.26%
Dec 31, 2025 3.52%
Sep 30, 2025 12.57%
Jun 30, 2025 4.81%
Mar 31, 2025 36.75%
Dec 31, 2024 32.91%
Sep 30, 2024 40.71%
Jun 30, 2024 29.50%
Mar 31, 2024 13.37%
Dec 31, 2023 39.85%
Sep 30, 2023 36.14%
Jun 30, 2023 31.82%
Mar 31, 2023 12.81%
Dec 31, 2022 -2.56%
Sep 30, 2022 -18.93%
Jun 30, 2022 -35.02%
Mar 31, 2022 -50.03%
Dec 31, 2021 -79.32%
Sep 30, 2021 -58.74%
Jun 30, 2021 -144.20%